文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

大非心脏手术前继续与停用肾素-血管紧张素系统抑制剂:Stop-or-Not 随机临床试验

Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01
一句话结论大非心脏手术前继续使用RASI不增加28天术后并发症,但术中低血压发生率更高(54% vs 41%)。

该多中心随机临床试验纳入2222例已服用RASI至少3个月并拟行大非心脏手术的患者,随机分为继续用药至手术日组(n=1107)或术前48小时停药组(n=1115)。主要终点28天全因死亡和主要术后并发症在停药组为22%(245/1115),继续组为22%(247/1107),风险比1.02(95%CI 0.87-1.19;P=0.85)。术中低血压在停药组为41%,继续组为54%,风险比1.31(95%CI 1.19-1.44)。结论认为继续RASI策略与停药策略相比不增加术后并发症,但术中低血压更常见。

要点

  • 大非心脏手术前继续RASI至手术日不增加28天全因死亡和主要术后并发症(22% vs 22%;RR 1.02,95%CI 0.87-1.19;P=0.85)。
  • 继续RASI组术中低血压发生率54%,高于停药组的41%(RR 1.31,95%CI 1.19-1.44)。
  • 停药策略为术前48小时停用RASI(即手术前3天服最后一次剂量)。
  • 研究纳入服用RASI至少3个月并拟行大非心脏手术的患者,46%用ACEI、54%用ARB。

适用人群与场景

  • 服用RASI(血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂)至少3个月、拟行大非心脏手术的患者。
  • 2018年1月至2023年4月法国40家医院纳入的成人患者(平均年龄67岁,SD 10岁;65%男性)。

处置流程与药物剂量

  • 继续策略:继续使用RASI直至手术当日。
  • 停药策略:术前48小时停用RASI(即手术前3天服用最后一次剂量)。

研究设计与关键结果

  • 随机临床试验,纳入2222例患者,40家法国医院,比较继续RASI(n=1107)与术前48小时停药(n=1115)策略。
  • 主要终点(28天内全因死亡和主要术后并发症复合终点):停药组22%(245/1115)vs 继续组22%(247/1107),风险比1.02(95%CI 0.87-1.19;P=0.85)。
  • 术中低血压:停药组41% vs 继续组54%,风险比1.31(95%CI 1.19-1.44)。
  • 其他次要终点(急性肾损伤、术后器官衰竭、28天内住院和ICU停留时间)无差异。

证据类型、等级与局限

  • 证据类型:随机临床试验(RCT)。
  • 试验注册号:ClinicalTrials.gov NCT03374449。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于服用RASI至少3个月并拟行大非心脏手术的患者,继续用药至手术日与术前48小时停药相比,28天全因死亡和主要术后并发症无差异。
  • 继续RASI策略术中低血压更常见(54% vs 41%),需在床旁权衡术中血流动力学管理。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Before surgery, the best strategy for managing patients who are taking renin-angiotensin system inhibitors (RASIs) (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) is unknown. The lack of evidence leads to conflicting guidelines.

OBJECTIVE: To evaluate whether a continuation strategy vs a discontinuation strategy of RASIs before major noncardiac surgery results in decreased complications at 28 days after surgery.

DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial that included patients who were being treated with a RASI for at least 3 months and were scheduled to undergo a major noncardiac surgery between January 2018 and April 2023 at 40 hospitals in France.

INTERVENTION: Patients were randomized to continue use of RASIs (n = 1107) until the day of surgery or to discontinue use of RASIs 48 hours prior to surgery (ie, they would take the last dose 3 days before surgery) (n = 1115).

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of all-cause mortality and major postoperative complications within 28 days after surgery. The key secondary outcomes were episodes of hypotension during surgery, acute kidney injury, postoperative organ failure, and length of stay in the hospital and intensive care unit during the 28 days after surgery.

RESULTS: Of the 2222 patients (mean age, 67 years [SD, 10 years]; 65% were male), 46% were being treated with angiotensin-converting enzyme inhibitors at baseline and 54% were being treated with angiotensin receptor blockers. The rate of all-cause mortality and major postoperative complications was 22% (245 of 1115 patients) in the RASI discontinuation group and 22% (247 of 1107 patients) in the RASI continuation group (risk ratio, 1.02 [95% CI, 0.87-1.19]; P = .85). Episodes of hypotension during surgery occurred in 41% of the patients in the RASI discontinuation group and in 54% of the patients in the RASI continuation group (risk ratio, 1.31 [95% CI, 1.19-1.44]). There were no other differences in the trial outcomes.

CONCLUSIONS AND RELEVANCE: Among patients who underwent major noncardiac surgery, a continuation strategy of RASIs before surgery was not associated with a higher rate of postoperative complications than a discontinuation strategy.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03374449.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Legrand M, Falcone J, Cholley B, et al. Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial. JAMA. 2024. PMID: 39212270. doi:10.1001/jama.2024.17123

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。